Tailored cancer cocktail tested for tough childhood tumor

NCT ID NCT02780128

Terminated Disease control Sponsor: Yael P Mosse Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tested a personalized approach for children with relapsed or hard-to-treat neuroblastoma. Doctors used a tumor biopsy to find genetic changes and then assigned a combination of targeted drugs (ceritinib and ribociclib) to match those changes. The study was terminated early, but it aimed to see if this strategy could shrink tumors and be safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ceritinib and ribociclib
What this could lead to: If successful, this approach could point toward more effective, personalized treatments for children with relapsed neuroblastoma.
What could go wrong: This was a very early (phase 1) trial that was terminated, so results are limited. The combination drugs may cause significant side effects and may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER NEUROBLASTOMA

Contacts and locations

Locations

The Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.